---
aliases: [MRNA]
---
#actor #healthcare #biotech #usa #public #ai

Moderna — mRNA platform company. COVID vaccine pioneer. Using AI for mRNA sequence optimization.

---

## Why Moderna matters

| Metric | Value |
|--------|-------|
| Market cap | ~$20B |
| Ticker | MRNA (NASDAQ) |
| Focus | mRNA vaccines and therapeutics |
| AI angle | Sequence design, manufacturing |

---

## mRNA + AI synergy

| Application | How AI helps |
|-------------|--------------|
| Sequence optimization | ML predicts optimal mRNA sequences |
| Lipid nanoparticles | AI designs delivery mechanisms |
| Manufacturing | Process optimization |
| Clinical trials | Patient selection, dosing |

Thesis: mRNA is software for biology; AI accelerates iteration cycles.

---

## Q4 2025 / FY 2025 (reported Feb 13, 2026)

Beat on both lines despite continued post-COVID normalization.

| Metric | Q4 2025 | FY 2025 | FY 2024 | YoY |
|--------|---------|---------|---------|-----|
| Revenue | $678M | $1.9B | ~$2.9B | -35% |
| Net loss | -$826M | — | — | — |
| EPS | -$2.11 | — | — | Beat -$2.60 est |
| Op expenses | — | -$2.2B vs target | — | Exceeded cost-cut target |

Key developments:
- FDA Refusal-to-File on US flu vaccine submission — regulatory setback
- Third commercial product launched (mNEXSPIKE)
- Three international manufacturing sites brought online
- Cash and investments: $8.1B at year-end + new credit facility

CEO [[Stéphane Bancel]]: Sharpened commercial execution, cost discipline. 2026 targets up to 10% revenue growth via mNEXSPIKE expansion and international partnerships.

2026 outlook: Up to 10% revenue growth. Multiple Phase 2/3 milestones expected.

---

## Pipeline

| Program | Status |
|---------|--------|
| COVID boosters | Commercial |
| RSV vaccine | Approved |
| mNEXSPIKE | Commercial (3rd product) |
| Flu vaccine | FDA Refusal-to-File (US) |
| Flu + COVID combo | Development |
| Cancer vaccines | Phase 2/3 |
| Rare diseases | Early stage |

---

## Investment case

Bull:
- Platform technology (not one-drug company)
- AI-native approach
- Cancer vaccine potential
- mRNA manufacturing expertise

Bear:
- Post-COVID revenue collapse
- Cash burn concerns
- Competition from Pfizer, BioNTech
- Cancer vaccines unproven at scale

---

## Related

- [[Pfizer]] — COVID vaccine partner (now competitor)
- [[Agentic AI]] — drug discovery applications
